Skip to content

Investigation on possible down-regulation of adverse effects of SARS-CoV-2 vaccination by type 2 allergic diseases using questionnaire to vaccine recipients

Investigation on possible down-regulation of adverse effects of SARS-CoV-2 vaccination by type 2 allergic diseases using questionnaire to vaccine recipients - Investigation on possible down-regulation of adverse effects of SARS-CoV-2 vaccination by type 2 allergic diseases using questionnaire to vaccine recipients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000044489
Enrollment
1000
Registered
2021-06-11
Start date
2021-06-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaccine adverse effects

Interventions

None listed

Sponsors

Allergic Disease Research Center, Chutoen General Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Workers in Chutoen General Medical Hospital who received Cominaty vaccine and approve this project.

Exclusion criteria

Exclusion criteria: Apparent loss or mistake in the questionnaire sheet.

Design outcomes

Primary

MeasureTime frame
Evaluation of differences in vaccine adverse effects (injection reactions [pain, swelling, and erythema], fever, headache, fatigability, muscle pain, joint pain, and others) between recipients who have present and past allergic diseases (atopic dermatitis, allergic rhinitis, bronchial asthma, and others) and those without these allergic diseases.

Secondary

MeasureTime frame
Evaluation of differences in the severity of vaccine adverse effects between recipients who have present and past allergic diseases (atopic dermatitis, allergic rhinitis, and bronchial asthma) and those without these allergic diseases.

Countries

Japan

Contacts

Public ContactYoshiki Tokura

Allergic Disease Research Center, Chutoen General Medical Center Allergic Disease Research Center

tokura@chutoen-hp.shizuoka.jp0537-21-5555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026